Clinical Trial

QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)

Name: QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH) — clinical trial record (NCT07450378)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This Phase III clinical trial aims to assess the efficacy and safety of QLC7401 Treatment in adults with Heterozygous Familial Hypercholesterolemia on a stable lipid-lowering therapy. Participants will be randomly assigned to receive subcutaneous injections of either QLC7401 or a placebo according to the study schedule.

Trial Details

NCT Number	NCT07450378
Lead Sponsor	Qilu Pharmaceutical Co., Ltd.
Conditions	Heterozygous Familial Hypercholesterolemia (HeFH)
Enrollment	120 participants
Start Date	2026-05
Primary Completion	2028-04 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2026-03-04